Aclaris Therapeutics Reports Phase 2 Bosakitug Miss and Advances Lichen Planus Trial

Aclaris Therapeutics reported that bosakitug failed to meet primary and secondary endpoints in its Phase 2 atopic dermatitis trial but was well tolerated. The company advanced its clinical pipeline, initiating a Phase 2b trial for modzatinib in lichen planus and planning Phase 1 and 2b trials for ATI-9494 and ATI-052, respectively, in 2027. According to the company, bosakitug showed target engagement and reduced immune-activation biomarkers.

Original reporting
Published Nov 16, 2026, 11:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aclaris Therapeutics Reports Phase 2 Bosakitug Miss and Advances Lichen Planus Trial — source image
Decision brief

The 30-second read

$ACRSBearishMed
01

Why it matters

The miss is likely to trigger a sell‑off, but the announced Phase 2b trials in lichen planus and upcoming IND filings may mitigate long‑term downside.

02

Market read

Immediate negative pressure on ACRS; longer‑term view depends on pipeline progress.

03

What to watch

Upcoming IND filing for ATI-9494 could provide upside if investors focus on pipeline depth.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

Aclaris Therapeutics (NASDAQ: ACRS) reported a Phase 2 trial miss for bosakitug in atopic dermatitis and announced new pipeline initiatives.

Company-level read

Ticker impact

$ACRSBearishHigh confidence
Context

Aclaris Therapeutics disclosed that its bosakitug Phase 2 trial missed primary and secondary endpoints, a material clinical setback.

Expected impact

likely downward pressure as market prices in the missed endpoints

Evidence & confidence

Phase 2 miss is a primary disclosure with material impact on biotech valuation.

Market effects

May dampen sentiment for dermatology and immunology biotech peers.

Limited to US biotech sector.

Low global impact beyond sector.

Counterpoint

If the company can pivot to its lichen planus trial, the miss may be priced out quickly.

Key entities

  • Aclaris Therapeutics

    Biotech firm developing dermatology and immunology therapies.

Related articles

$ACRSMedAI 8/10

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSHighAI 8/10

Aclaris stock falls after atopic dermatitis trial fails

Aclaris Therapeutics (NASDAQ:ACRS) shares dropped 6% after its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet primary and secondary endpoints. The trial evaluated bosakitug (ATI-045), which showed target engagement but did not improve Eczema Area and Severity Index scores. The company remains focused on other treatments, including modzatinib (ATI-2138) for lichen planus, with a Phase 2b trial underway.

$ACRSHighAI 8/10

Aclaris Therapeutics’ mAb fails in Phase II eczema trial

Aclaris Therapeutics' Phase II trial of bosakitug for atopic dermatitis failed to meet primary and secondary endpoints, though the drug showed target engagement. The company remains focused on other treatments, including modzatinib and ATI-052. The atopic dermatitis market is projected to grow to $21.5bn by 2033, with key players like Sanofi and AbbVie.